You are here: Home / About the Faculty / Faculty Staff / Academic Staff

Michael Murray

Professor of Pharmacogenomics (Pharmaceutics)

Qualifications

B Pharm (Hons I) Sydney 1978
PhD Sydney 1982
DSc Sydney 1996

Contact details

University of Sydney
Main Campus
Phone: +61 2 9351 2326
Fax: +61 2 9351 6950
Email:
Room S345
Pharmacy Building A15
The University of Sydney
NSW 2006 Australia

Medical Foundation Building:
Phone: +61 2 9036 3259
FAX: +61 2 9351 4447
Room 105
Medical Foundation Building K25
The University of Sydney
NSW 2006 Australia

Research Interests

  • Human drug metabolism
  • Cytochrome P450 (CYP) pharmacogenetics
  • CYP regulation by drugs, nutrients and endobiotics
  • Adverse drug reactions caused by reactive drug metabolites
  • Drug-drug interactions due to inhibition of P450 enzymes

Track Record

Michael Murray graduated with a Bachelor of Pharmacy with First Class Honours and a Ph.D. in Pharmaceutical Chemistry from the University of Sydney. After undertaking postdoctoral research with CF Wilkinson in the Institute for Comparative and Environmental Toxicology at Cornell University, Ithaca, NY he returned to Westmead Hospital and was appointed as an HMRC Research Fellow in 1987, promoted to NHMRC Senior Research Fellow in 1989 and to NHMRC Principal Research Fellow in 1994. In 1995 he received a D.Sc. from The University of Sydney. After 5 years at UNSW in The School of Physiology and Pharmacology, he returned in July, 2003 to the University of Sydney's Faculty of Pharmacy to take up the inaugural Chair of Pharmacogenomics. The Pharmacogenomics and Drug Development research laboratory is located in the Faculty's new laboratories in the Medical Foundation Building.

Michael Murray is the author of 128 original papers and 24 review articles since 1982 and has presented 68 invited seminars, workshops and symposia in Australia, North America, Singapore and the United Kingdom. He was the 2002 ASCEPT visitor to the British Toxicology Society. He has been associated with the International Society for the Study of Xenobiotics (as Councillor 1986-1989), the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (Councillor and convenor of the Drug Metabolism, Delivery and Pharmacokinetics section 2000-2003 and Deputy Chair of the Scientific Advisory Committee 2002-present) and the Gastroenterological Society of Australia (Research Advisory Committee 1989-1995). He currently serves on the editorial boards of Toxicology and Applied Pharmacology and Xenobiotica and was a recent member of the editorial board of the Journal of Gastroenterology and Hepatology.

Back to Top

Research Personnel

  • Dr Sarah Cui (Postdoctoral Associate)
  • Dr Andy Lee (Postdoctoral Associate)
  • Dr Keryn Lucas (Postdoctoral Associate)
  • Dr Tristan Rawlings (Postdoctoral Associate)
  • Dorothy To (PhD Candidate)
  • Several Pharmacy (advanced) and Visiting international students
Back to Top

Scientific Collaborations

  • Dr Rob Edwards (Clinical Pharmacology, Imperial College, University of London, Hammersmith Hospital)
  • Prof Iqbal Ramzan (Faculty of Pharmacy)
  • A/Prof Howard Gurney (Department of Medical Oncology, Westmead Hospital)
  • Prof Andrew McLachlan (Faculty of Pharmacy)
Back to Top

Research Publications 2002-present

  1. L Liu, M Murray and E Burcher. Structure-activity studies of bufokinin, substance P and their C-terminal fragments at bufokinin receptors in the small intestine of the cane toad, Bufo marinus. Biochem Pharmacol 63, 217-224 (2002).
  2. I Stupans, HW Tan, A Kirlich, K Tuck, P Hayball and M Murray. Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 54, 269-275 (2002).
  3. M Murray. Pharmacogenetic variation in drug oxidizing CYPs: Impact on drug therapy, drug safety and drug interactions. Current Pharmacogenomics 1, 159-173 (2003).
  4. M Murray, E Fiala-Beer and D Sutton. Upregulation of cytochromes 2B in rat liver by orphenadrine.Brit J Pharmacol 139, 787-796 (2003).
  5. NY Marden, E Fiala-Beer, SH Xiang and M Murray. Role of Activator Protein-1 in the downregulation of the human CYP2J2 gene in hypoxia. Biochem J 373, 669-680 (2003).
  6. M Murray and K Murray. Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines. Xenobiotica 33, 973-987 (2003).
  7. L Liu, I Markus, R Vandenberg, BA Neilan, M Murray and E Burcher. Molecular identification and characterization of three isoforms of tachykinin NK1-like receptors in the cane toad, bufo marinus. Am J Physiol (Regulat Integrat and Comp Physiol) 287, R575-R585 (2004).
  8. M Murray and AM Butler. Comparative inhibition of inducible and constitutive CYPs in rat hepatic microsomes by parathion. Xenobiotica 34, 723-739 (2004).
  9. M Murray. Review of "Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma." Breast Canc Online 7: #10 (2004).
  10. L Liu, M Murray, JM Conlon and E Burcher. Quantitative structure-activity analyses of bufokinin and other tachykinins at bufokinin (bNK1) receptors of the small intestine of the cane toad, Bufo marinus. Biochem Pharmacol 69, 329-338 (2005).
  11. GM Su, E Fiala-Beer, J Weber, D Jahn, GR Robertson and M Murray. Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochem Pharmacol 69, 709-717 (2005).
  12. M Murray, AM Butler, E Fiala-Beer and GM Su. Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. FEBS Letters 579, 3669-3673 (2005).
  13. NY Marden and M Murray. Characterisation of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. Biochem J 391, 631-640 (2005).
  14. C Cowpland, GM Su, M Murray, IB Puddey and KD Croft. The effect of alcohol on cytochrome P450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clin Exp Pharmacol Physiol 33, 183-188 (2006).
  15. M. Murray. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Current Drug Metab 7, 67-81 (2006).
  16. R Obligacion, M Murray and I Ramzan. Drug metabolising enzymes and transporters: Expression in the human prostate and roles in prostate drug disposition. J Androl 27, 138-150 (2006).
  17. M Murray. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58, 871-885 (2006).
  18. M Murray and N Petrovic. Cytochromes P450: Decision making tools for personalized therapeutics. Curr Opin Mol Ther 8, 480-486 (2006).
  19. M Murray. Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opin Drug Metab Toxicol 3, 185-196 (2007).
  20. M Chetty and M Murray. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8, 307-313 (2007).
  21. E Fiala-Beer, AC Lee and M Murray. Regulation of the rat CYP4A2 gene promoter by c-Jun and octamer binding protein-1. Int J Biochem Cell Biol 39, 1235-1247 (2007).
  22. WV Zhang, I Ramzan and M Murray. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther 322, 770-777 (2007).
  23. H Xu, K Williams, W Liauw, M Murray, RO Day, and AJ McLachlan. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Brit J Pharmacol 153, 1579-1586 (2008).
  24. M Szymczak, M Murray and N Petrovic. Modulation of angiogenesis by w-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 111, 3514-3521 (2008).
  25. X Rong, MS Kim, N Su, S Wen, Y Matsuo, J Yamahara, M Murray and Y Li. An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats. Food Chem Toxicol 46, 2165-2172 (2008).
  26. M Murray. Modulation of cytochromes P450 by phytochemicals. Invited chapter in Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics, edited by C. Ioannides (Royal Society of Chemistry). Chapter 14, pp449-479, 2008.
  27. N Petrovic and M Murray. Modulation of tumor angiogenesis by polyunsaturated fatty acids: what is the mechanism? "Invited chapter in Oncogene Proteins: Structure, Functions and Analyses, edited by PB Murphy and JR Clarke (Nova Science Publishers Inc., Hauppauge, USA), Chapter 4, pp121-142, 2008.
  28. Y Li, Y Qi, MS Kim, KZY Xu, THW Huang, X Rong, M Murray and J Yamahara. Increased renal collagen cross-linking and lipid accumulation in nephropathy of Zucker diabetic fatty rats. Diabetes Metab Res Rev 24, 498-506 (2008).
  29. WV Zhang, F d’Esposito, RJ Edwards, I Ramzan and M Murray. Inter-individual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to CYP-specific inhibition in human hepatic microsomes. Drug Metab Dispos 36, 2547-2555 (2008).
  30. F d’Esposito, BN Tattam, I Ramzan and M Murray. A liquid chromatography/electrospray ionization mass spectrometry (LC/MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. J Chromatogr B 875, 522-530 (2008).
  31. S Ghassabian, M Chetty, BN Tattam, J Glen, J Rahme, Z Stankovic, I Ramzan, M Murray and AJ McLachlan. A high-throughput assay using liquid chromatography/tandem mass spectrometry for simultaneous in vivo phenotyping of five major cytochrome P450 enzymes in patients. Ther Drug Monit, in press.
  32. PH Cui, WV Zhang, J Hook, BN Tattam, CC Duke and M Murray. Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides. Chem Phys Lipids, in press.
Back to Top

Research Funding 2002-present

2000-2002 M. Murray. National Health and Medical Research Council Project Grant. "Impaired regulation of cytochromes P450 during the evolution of hepatic steatosis." $182,359.
2001-2003 M. Murray. National Health and Medical Research Council Project Grant. "Hypoxia and the transcriptional regulation of CYP genes in cells." $210,000
2001-2003 M. Murray and G.A. Smythe. Australian Research Council Large Grant. "Structural differences in CYP2 family proteins that control substrate specificity." $181,350.
2004-2006 M. Murray and G.R. Robertson. National Health and Medical Research Council Project Grant. "Alternate signalling pathways regulating the human arachidonate epoxygenase CYP2J2 in response to stress stimuli."$363,000.
2004-2006 M. Murray and T.J.R Lambert. National Health and Medical Research Council Project Grant. "Clozapine toxicity: Role of pharmacogenetic variation in CYP enzymes and bioactivation mechanisms in patient neutrophils"$330,375.
2004-2005 M. Murray and S.J. Clarke. University of Sydney Cancer Research Fund Project Grant. "Impact of human cytochrome P450 3A allelic variants on the toxicity of docetaxel and irinotecan." $98,000.
2004 M. Murray. University of Sydney, Sesqui Major Equipment Grant Funding. "Wallac Victor Multilabel reader." $96,000
2005 R.J. Trent, N.H. Hunt, I.W. Dawes, P.F. Little, P.L. Bergquist, M.S. Baker, R.J. Scott, P.R. Dunkley, M. Murray, T. Chan-Ling and C.R. MacKay. ARC - Linkage, Infrastructure, Equipment and Facilities Grant Funding. "Phenotype genotype comparisons using functional genomic approaches." $509,131
2005

N.J. King, I.W. Dawes, L.M. Kachigian, K.W. Beagley, I.L. Campbell, D.I. Cook, J. Black, G. Halliday, J.W. McAvoy, N.H. Hunt, P.W. Gunning, J.D. Pollard, M. Murray and W.J. Britton. ARC - Linkage, Infrastructure, Equipment and Facilities Grant Funding. "Advanced Imaging Flow Cytometry Facility for NSW."
2006-2008 M Murray. National Health and Medical Research Council Project Grant. "Novel omega-3 fatty acid epoxides and the activation of cellular survival pathways." $447,750
2007-2009 M Murray. National Health and Medical Research Council Project Grant. "Functional interplay of transcriptional activators in the regulation of the cytoprotective human CYP2J2 gene" $462,000.
2007

H Chan, PJ Stewart, IC Larson, PM Young, D Traini, AS Weiss, M Murray, F Dehghani, DE Hibbs and GG Warr. Australian Research Council Linkage, Infrastructure, Equipment and Facilities Grant. "State-of-the-art high resolution thermal analysis suite for the life and material sciences." $100,000.
2008 J Hanrahan, D Hibbs, M Collins and M Murray. Clive and Vera Ramaciotti Foundations. “A 400 MHz Nuclear Magnetic Resonance (NMR) Spectrometer.” $30,000.
2008 M Murray, JR Hanrahan, DE Hibbs, BD Roufogalis, M Collins, CC Duke, WB Church, IR Kennedy, GAR Johnston, DR Richardson, N Manolios, R Codd, RD Allan, M Kassiou, M Ali and BN Tattam. National Health and Medical Research Council Equipment Grant. “Varian NMR System 400MHz & Autosampler”. $100,000.
2009 BD Roufogalis, DE Hibbs, JR Hanrahan, M Murray and CC Duke. Clive and Vera Ramaciotti Foundations. Bruker APEX II X-ray diffractometer detector. $30,000.
2009-2011 M Murray. National Health and Medical Research Council Project Grant. "Cytochrome P450-mediated epoxides of polyunsaturated fatty acids that regulate cell death and survival." $476,250.
2009-2011 M Murray, H Gurney and AJ McLachlan. Cancer Council NSW Project Grant. “Development of personalized dosage protocols for tyrosine kinase inhibitors in oncology patients.” $288,650 for 3 years.
2009 DE Hibbs, BD Roufogalis, M Murray, TW Hambley, JR Hanrahan, WB Church, M Collins, GAR Johnston, PM Young and D Traini. National Health and Medical Research Council Equipment Grant. “Bruker APEX II CCD Detector: Fourth generation APEX II ultra-low noise CCD X-ray detector with 16 megapixel chip.” $100,000

Back to Top